Limitations of the Study
Although our study was a multi-center trial, it was limited by a retrospective design and relatively small number of patients because MA-PVCs are comparatively rare arrhythmias. The patients in this study were also limited by having a high frequency of %PVCs (mean %PVC = 20.1 ± 8.6%) and disabling symptoms. Thus, the effect of the RFCA of the MA-PVCs in patients with a low frequency of %PVCs and/or asymptomatic patients was unfortunately unknown in this study. Moreover, our study could not clarify the long term clinical benefit of RFCA of MA-PVCs. Thus, whether our results can safely be extrapolated to the inclusion of a larger number of patients, whether the use of contact force catheters, and whether a longer follow-up period in these patients is needed should be determined in further studies.